PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 3, 2013, Pages 377-385

  Zhu, Shudong ^a,b   Cohen, Matthew B ^a   Bjorge, Jeffrey D ^c   Mier, James W ^a   Cho, Daniel C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Southern Alberta Cancer Research Institute   (Canada)

Author keywords

Apoptosis; Bcl 2; PI3K; Renal carcinoma cell; XIAP

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT-737; BIPHENYL DERIVATIVE; CASPASE 3; CASPASE 8; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; MYELOID LEUKEMIA FACTOR 1; NITROPHENOL; PHOSPHATIDYLINOSITOL 3 KINASE; PIPERAZINE DERIVATIVE; PROTEIN BCL 2; SULFONAMIDE; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CASPASE 3; CASPASE 8; CELL PROLIFERATION; CHROMONES; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; KIDNEY NEOPLASMS; MORPHOLINES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR CELLS, CULTURED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84875799486     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12019     Document Type: Article

References (24)

1. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81.
2. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008; 372: 449-56.
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296: 1655-7.
4. del Peso L, Gonzales G-M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997; 278: 687-9.
5. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998; 282: 1318-21.
6. Kim AH, Khursigara G, Sun X, et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001; 21: 893-901.
7. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96: 857-68.
8. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999; 401: 86-90.
9. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 1998; 273: 32377-9.
10. Cragg MS, Harris C, Strasser A, et al. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer. 2009; 9: 321-6.
11. Boccellino M, Giuberti G, Quagliuolo L, et al. Apoptosis induced by interferon-alpha and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells. J Cell Physiol. 2004; 201: 71-83.
12. Panaretakis T, Pokrovskaja K, Shoshan MC, et al. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem. 2002; 277: 44317-26.
13. Chandra D, Liu J, Tang DG. Early mitochondrial activation and cytochrome c up-regulation during apoptosis. J Biol Chem. 2002; 277: 50842-54.
14. Qian J, Zou Y, Rahman JS, et al. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther. 2009; 8: 101-9.
15. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006; 7: 988-94.
16. Mizutani Y, Nakanishi H, Li YN, et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncology. 2007; 30: 919-25.
17. Bilim V, Yuuki K, Itoi T, et al. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer. 2008; 98: 941-9.
18. Chan G, Nogalski MT, Bentz GL, et al. PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes. J Immunol. 2010; 184: 3213-22.
19. Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA. 2009; 106: 19503-8.
20. Wesarg E, Hoffarth S, Wiewrodt R, et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer. 2007; 121: 2387-94.
21. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10: 375-88.
22. Czabotar PE, Colman PM, Huang DC. Bax activation by Bim? Cell Death Differ. 2009; 16: 1187-91.
23. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292: 727-30.
24. Würstle ML, Laussmann MA, Rehm M. The caspase-8 dimerization/dissociation balance is a highly potent regulator of caspase-8, -3, -6 signaling. J Biol Chem. 2010; 285: 33209-18.